se I Clinical Trial of Long Acting
Selected Abstract
Novo Nordisk and Neose Announce Initiation of Phase I Clinical Trial of Long-Acting Factor VIIa.
COPENHAGEN, Denmark & HORSHAM, Pa. -- Novo Nordisk A/S (NYSE:NVO) and Neose Technologies, Inc. (NasdaqGM:NTEC) today announced that Novo Nordisk has initiated a Phase I clinical trial of GlycoPEGylated Factor VIIa, a long-acting version of NovoSeven[R] Coagulation Factor VIIa (Recombinant). The ... June 15, 2007; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles No Results Found.
|
